Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Just For You This ETF Is Proof That the Healthcare Rebound Is RealSubmitted by Jordan Chussler. Posted: 1/11/2026. 
Key Takeaways - After years of trailing the S&P 500, health care has rebounded, leading all other sectors with a 19% gain over the past six months.
- The bullish case for that rally to continue involves America’s GLP-1 drug obsession and incredibly low health care stock valuations.
- The Vanguard Health Care ETF provides broad exposure and is off to a strong start in 2026.
With well-publicized losses for companies including UnitedHealth Group (NYSE: UNH), Elevance Health (NYSE: ELV), and Wegovy and Ozempic maker Novo Nordisk (NYSE: NVO), the healthcare sector failed to outperform the broad market last year. In the three years before the recent rebound, the sector posted modest returns: 2.6% in 2024, 2.1% in 2023 and a 2.0% loss in 2022. Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund.
It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you."
This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight. Click here for the full story. But healthcare stocks appear to have turned a corner. Over the past six months, the sector—which benefits from inelastic demand—has led all 11 sectors of the S&P 500 with a nearly 19% gain. Investment professionals say the trend that began in mid-2025 is likely to continue into the new year. For shareholders of the Vanguard Health Care ETF (NYSEARCA: VHT), that is already proving true. 2 Major Catalysts for the Health Care Sector Two major tailwinds should help health stocks sustain this bullish momentum. One—the mass adoption of weight-loss drugs—helped spark the sector's reversal in mid-2025. The other—comparatively low valuations—could keep attracting inflows as investors look to lock in profits and hedge against more volatile positions. America's Weight-Loss Treatment Craze GLP-1 agonists, including semaglutide-based products such as Novo Nordisk's Ozempic and Wegovy, are becoming widely adopted. At the same time, pharmaceutical companies are shifting from injectable treatments to pill form, while others, like Pfizer (NYSE: PFE), are doubling down on investments in the weight-loss market. Speaking about the popularity of these drugs, Catherine Brown, vice president of clinical services at digital health firm Welldo, recently told Reuters that "We're imagining these medications may become so common that everybody's got a GLP-1 app ... right there on your phone next to your bank account." Forecasts from industry consultancy Grand View Research indicate the GLP-1 drug market could grow at a compound annual growth rate of 18.54% between 2024 and 2030, expanding the global market from $13.84 billion to $48.84 billion. Low Health Care Valuations Are Attracting Inflows Following President Trump's tariff announcements in April 2025—which affected imported pharmaceuticals—many health care stocks began trading at remarkably low valuations, especially when compared with historically high multiples in the technology and communication services sectors. Pfizer, for example, has a trailing 12-month (TTM) price-to-earnings (P/E) ratio of 14.7, while health benefits provider Elevance and Johnson & Johnson (NYSE: JNJ) carry P/E multiples of 15.32 and 19.86, respectively. By contrast, tech favorites such as Palantir (NASDAQ: PLTR) and Tesla (NASDAQ: TSLA) have TTM P/E multiples of 421.11 and 290.53, respectively. It was therefore only a matter of time before health care's lower ratios attracted value-oriented investors late in 2025 and into 2026. In November 2025, Mizuho's healthcare equity strategist Jared Holz told Barron's, "When you see money come out of a space, especially one that's filled with trillion-dollar [tech] companies, it really doesn't take much to get some of the underperforming sectors a little juice." Vanguard's VHT: A Basket of Undervalued Stocks The Vanguard Health Care ETF is up 2.30% this year after gaining more than 18% over the past six months. Many of those gains were fueled by rebounds and strong end-of-year performances from the fund's top holdings. Those positions include the ETF's top five holdings: Eli Lilly (NYSE: LLY), AbbVie (NYSE: ABBV), Johnson & Johnson, UnitedHealth, and Merck (NYSE: MRK). Looking deeper into its allocations, VHT also holds Pfizer, CVS Health (NYSE: CVS)—which acquired Aetna in 2018—and the United States' largest hospital chain, HCA Healthcare (NYSE: HCA). The ETF carries a low expense ratio of 0.09% and pays a dividend that currently yields 1.58%, or $4.64 per share annually. What Wall Street Thinks About VHT Based on analysts' ratings of 23 companies in the VHT portfolio (covering 64.3% of its holdings), the fund receives a Moderate Buy rating. Perhaps the strongest sign of Wall Street's renewed interest in the health care sector is the ETF's current short interest of just 0.33% of the float—fewer than 195,000 shares of the 60.17 million shares outstanding. That represents a nearly 37% decrease in short interest since the last reporting period.
| 
